Questo articolo fornisce linee guida aggiornate per la valutazione diagnostica, […]
Search Results for: Identificata la causa della progressione dell’Alzheimer nel cervello
Here's what we've found for you
Endometriosis and Ovarian Cancer
To the Editor As noted by Dr Barnard and colleagues, existing evidence confirms that endometriosis is associated with an elevated risk of ovarian cancer with differences by histotype. However, despite the varying presentations of endometriosis—most notably 3 macrosurgically visualized subphenotypes (endometriomas, superficial peritoneal, and/or deep lesions)—identifying women with endometriosis who are at high risk remains elusive. To address this question, the investigators leveraged data from the Utah Population Database and defined endometriosis subphenotypes by International Classification of Diseases (ICD) codes documented from 1992 to 2019 in more than 450 000 women. A consistent challenge in registry-based studies has been the selection of a comparison group. As demonstrated by Hermens et al in the Dutch nationwide registry, women diagnosed with ovarian cancer may be concurrently diagnosed with endometriosis, biasing estimated risk compared with members of the general population, who typically have not had pelvic surgery and whose endometriosis is more likely to remain undetected, leading to an observed 29 (95% CI, 20.7-40.9) times greater risk of endometrioid ovarian cancer (incident rate per 100 000 person-years, 29.7) when they included concurrent endometriosis diagnosis, but a much lower 2.6 (95% CI, 1.5-4.5)–fold greater risk when they excluded endometriosis diagnosed within 1 year of a diagnosis of ovarian cancer (incident rate per 100 000 person-years, 4.1). Unfortunately, Barnard and colleagues did not exclude concurrent diagnoses of ovarian cancer and endometriosis (17% of endometriosis and ovarian cancer diagnoses were within 5 mm under the peritoneal surface). Furthermore, since deep lesions were combined with endometriomas, the reader is unable to distinguish the true ovarian cancer risk for women with endometriomas vs deep lesions. Ultimately, the results may encourage clinicians to advise women with endometriomas or deep endometriosis toward prophylactic bilateral oophorectomy based on an overestimation of the true risk. Such an approach disregards the growing evidence of harm caused by inducing early menopause unnecessarily, including elevated risk of cardiovascular disease, bone fracture, and Alzheimer disease. As this is an essential question for women’s health, a reanalysis of the data are needed to guide women and clinicians in understanding a realistic estimation of their ovarian cancer risk and valid attribution to an accurately defined endometriosis subtype.
Alzheimer, svelato un meccanismo chiave per rallentarlo
Protagoniste le cellule immunitarie del cervello
Primo studio clinico di successo per un farmaco contro l’Alzheimer
I ricercatori del Warren Center for Neuroscience Drug Discovery, un […]
Da sonno a dieta, 8 abitudini per mantenere giovane il cervello
Per ogni 10 punti in più di aderenza,dimostra 113 giorni in meno
Alzheimer, alcuni casi legati a citomegalovirus nell'intestino
Virus salirebbe al cervello per il nervo vago favorendo malattia
In Congo una 'forma grave di malaria'. Una morte sospetta in Veneto
La Regione avvia accertamenti con lo Spallanzani. Per il paese africano la malattia misteriosa “è una grave forma di malaria”, ma per l’Oms non è ancora determinata la causa
Torna dal Congo e muore in Veneto per una febbre con emorragia
La Regione avvia accertamenti con lo Spallanzani. Per il paese africano la malattia misteriosa “è una grave forma di malaria”, ma per l’Oms non è ancora determinata la causa
A Chieti test con prelievo di sangue per diagnosticare Alzheimer
‘Cast’ analizza il plasma con un sistema a chemiluminescenza
Vascular Neurology Considerations for Antiamyloid Immunotherapy: A Science Advisory From the American Heart Association
Stroke, Ahead of Print. Antibodies directed at the amyloid-β peptide offer the prospect of disease-modifying therapy for early-stage Alzheimer disease but also carry the risk of brain edema or bleeding events, collectively designated amyloid-related imaging abnormalities. Introduction of the antiamyloid immunotherapies into practice is therefore likely to present a new set of questions for clinicians treating patients with cerebrovascular disease: Which manifestations of cerebrovascular disease should preclude, or permit, antibody treatment? Is it safe to prescribe amyloid immunotherapies to individuals who require antithrombotic treatment, or to administer thrombolysis to antibody-treated individuals with acute stroke? How should severe amyloid-related imaging abnormalities be managed? This science advisory summarizes the data and key considerations to guide these challenging decisions as the medical community collects further data and experience with these groundbreaking agents.
Scompenso cardiaco, test per un vaccino protettivo italiano
Reazione autoimmune alla base della progressione della malattia
Gastrointestinal syndromes in Parkinsons disease: risk factors or comorbidities?
With great interest, we read the article by Konings et al,1 in which the authors conducted a combined case–control and cohort study and found that dysphagia, gastroparesis, irritable bowel syndrome (IBS) without diarrhoea and constipation specifically predict subsequent newly onset idiopathic Parkinson’s disease (PD) through comparing patients with PD with matched negative controls and patients with Alzheimer’s disease (AD) and cerebrovascular diseases (CVDs). However, several methodological concerns should be carefully addressed before concluding that those gastrointestinal (GI) syndromes can predict the development of PD. First, reverse causation from the diagnostic delay of neurodegenerative diseases is a big concern,2 3 and not considering it in the analysis might lead to spurious associations (eg, the short-term increased PD risk after Clostridium difficile infection4). Given this diagnostic delay, the temporal relationship between GI syndromes and neurodegenerative disease in Konings et al’s study1…
Scompenso cardiaco, test per un vaccino protettivo italiano
Reazione autoimmune alla base della progressione della malattia
Payer Coverage Considerations for Alzheimer Disease Blood-Based Biomarker Tests
This Viewpoint discusses proactively preparing to make informed payer coverage decisions to help address current disparities in Alzheimer disease diagnosis and treatment.
Oms, in Congo 406 casi e 31 i morti per causa sconosciuta
Più di una malattia può contribuire alla mortalità
Da Alzheimer a infarto, l'occhio svela malattie ed età biologica
Con l’esame esterno possibile anche un check-up della salute